ZA992255B - Antitumor synergetic composition. - Google Patents

Antitumor synergetic composition.

Info

Publication number
ZA992255B
ZA992255B ZA9902255A ZA992255A ZA992255B ZA 992255 B ZA992255 B ZA 992255B ZA 9902255 A ZA9902255 A ZA 9902255A ZA 992255 A ZA992255 A ZA 992255A ZA 992255 B ZA992255 B ZA 992255B
Authority
ZA
South Africa
Prior art keywords
antitumor
synergetic composition
synergetic
composition
antitumor synergetic
Prior art date
Application number
ZA9902255A
Other languages
English (en)
Inventor
Cristina Geroni
Marina Ripamonti
Michele Caruso
Antonino Suarato
Original Assignee
Pharmacia & Upjohn Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Spa filed Critical Pharmacia & Upjohn Spa
Publication of ZA992255B publication Critical patent/ZA992255B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA9902255A 1998-03-24 1999-03-23 Antitumor synergetic composition. ZA992255B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9806324.1A GB9806324D0 (en) 1998-03-24 1998-03-24 Antitumour synergetic composition

Publications (1)

Publication Number Publication Date
ZA992255B true ZA992255B (en) 1999-10-05

Family

ID=10829188

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9902255A ZA992255B (en) 1998-03-24 1999-03-23 Antitumor synergetic composition.

Country Status (29)

Country Link
US (1) US6403563B1 (uk)
EP (1) EP1067941B1 (uk)
JP (1) JP2002507571A (uk)
KR (1) KR20010034619A (uk)
CN (2) CN1150002C (uk)
AR (1) AR018166A1 (uk)
AT (1) ATE271388T1 (uk)
AU (1) AU758191B2 (uk)
BR (1) BR9908391A (uk)
CA (1) CA2324610A1 (uk)
CZ (1) CZ295368B6 (uk)
DE (1) DE69918819T2 (uk)
DK (1) DK1067941T3 (uk)
EA (1) EA003134B1 (uk)
ES (1) ES2226366T3 (uk)
GB (1) GB9806324D0 (uk)
HU (1) HUP0101615A3 (uk)
ID (1) ID26091A (uk)
IL (1) IL138035A0 (uk)
MY (1) MY133016A (uk)
NO (1) NO20004703L (uk)
NZ (1) NZ507570A (uk)
PL (1) PL343098A1 (uk)
PT (1) PT1067941E (uk)
SI (1) SI1067941T1 (uk)
TW (1) TW576740B (uk)
UA (1) UA63000C2 (uk)
WO (1) WO1999048503A1 (uk)
ZA (1) ZA992255B (uk)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6820065B1 (en) * 1998-03-18 2004-11-16 Ascom Hasler Mailing Systems Inc. System and method for management of postage meter licenses
GB9904387D0 (en) * 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
GB9909925D0 (en) * 1999-04-29 1999-06-30 Pharmacia & Upjohn Spa Combined preparations comprising anthracycline derivatives
GB9916882D0 (en) * 1999-07-19 1999-09-22 Pharmacia & Upjohn Spa Antitumor synergistic composition
GB9926843D0 (en) * 1999-11-12 2000-01-12 Pharmacia & Upjohn Spa Lipid complex of alkycyclines
US6627614B1 (en) * 2002-06-05 2003-09-30 Super Gen, Inc. Sequential therapy comprising a 20(S)-camptothecin and an anthracycline
EP1985286A1 (en) * 2007-04-24 2008-10-29 Biocompatibles UK Limited Microspheres for treatment of brain tumours
US8349764B2 (en) 2007-10-31 2013-01-08 Molycorp Minerals, Llc Composition for treating a fluid
US20090107925A1 (en) * 2007-10-31 2009-04-30 Chevron U.S.A. Inc. Apparatus and process for treating an aqueous solution containing biological contaminants
US20110207760A1 (en) * 2010-02-23 2011-08-25 Valery Alakhov Sn-38 compositions
WO2011160063A2 (en) 2010-06-18 2011-12-22 Myriad Genetics, Inc. Methods and materials for assessing loss of heterozygosity
DK2609216T3 (en) 2010-08-24 2016-09-12 Dana Farber Cancer Inst Inc Methods to predict anti-cancer response
US9233863B2 (en) 2011-04-13 2016-01-12 Molycorp Minerals, Llc Rare earth removal of hydrated and hydroxyl species
EP2721181B1 (en) 2011-06-17 2019-12-18 Myriad Genetics, Inc. Methods and materials for assessing allelic imbalance
AU2012358244A1 (en) 2011-12-21 2014-06-12 Myriad Genetics, Inc. Methods and materials for assessing loss of heterozygosity
NZ628813A (en) 2012-02-23 2015-10-30 Univ Denmark Tech Dtu Methods for predicting anti-cancer response
CA3190075A1 (en) 2012-06-07 2013-12-12 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
US10308986B2 (en) 2013-03-14 2019-06-04 Children's Medical Center Corporation Cancer diagnosis, treatment selection and treatment
AU2014248007B2 (en) 2013-04-05 2020-03-26 Myriad Genetics, Inc. Methods and materials for assessing homologous recombination deficiency
US11149316B2 (en) 2013-12-09 2021-10-19 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (BRCA1/2) in human tumors
MX370462B (es) 2014-03-07 2019-12-13 Secure Natural Resources Llc Oxido de cerio (iv) con propiedades de remocion de arsenico excepcionales.
DK3180447T3 (da) 2014-08-15 2020-06-15 Myriad Genetics Inc Fremgangsmåder og materialer til analyse af homolog rekombinationsdeficiens
EP4141127A1 (en) 2021-08-30 2023-03-01 Zentrum Familiärer Brust- und Eierstockkrebs Universitätsklinik Köln Method for assessing homologous recombination deficiency in ovarian cancer cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9114549D0 (en) * 1991-07-05 1991-08-21 Erba Carlo Spa Mono and bis alkylamino-anthracyclines
GB9325417D0 (en) * 1993-12-13 1994-02-16 Erba Carlo Spa 3'- aziridino-anthracycline derivatives

Also Published As

Publication number Publication date
ATE271388T1 (de) 2004-08-15
NZ507570A (en) 2003-01-31
MY133016A (en) 2007-10-31
IL138035A0 (en) 2001-10-31
EP1067941A1 (en) 2001-01-17
WO1999048503A1 (en) 1999-09-30
NO20004703D0 (no) 2000-09-20
HUP0101615A2 (hu) 2001-10-28
CZ20003493A3 (cs) 2001-02-14
DK1067941T3 (da) 2004-11-29
NO20004703L (no) 2000-09-20
GB9806324D0 (en) 1998-05-20
PT1067941E (pt) 2004-12-31
US6403563B1 (en) 2002-06-11
AU3331499A (en) 1999-10-18
CZ295368B6 (cs) 2005-07-13
BR9908391A (pt) 2000-10-31
UA63000C2 (en) 2004-01-15
SI1067941T1 (en) 2005-02-28
ID26091A (id) 2000-11-23
HUP0101615A3 (en) 2002-12-28
EA200000978A1 (ru) 2001-02-26
EA003134B1 (ru) 2003-02-27
TW576740B (en) 2004-02-21
JP2002507571A (ja) 2002-03-12
CN1294516A (zh) 2001-05-09
CA2324610A1 (en) 1999-09-30
ES2226366T3 (es) 2005-03-16
DE69918819T2 (de) 2005-08-18
EP1067941B1 (en) 2004-07-21
CN1150002C (zh) 2004-05-19
DE69918819D1 (de) 2004-08-26
KR20010034619A (ko) 2001-04-25
AR018166A1 (es) 2001-10-31
AU758191B2 (en) 2003-03-20
PL343098A1 (en) 2001-07-30
CN1528334A (zh) 2004-09-15

Similar Documents

Publication Publication Date Title
ZA992255B (en) Antitumor synergetic composition.
ZA996185B (en) Sulfanylsilanes.
HK1053050A1 (en) Bra.
ZA9811959B (en) Ibuprofen composition.
HK1038690A1 (en) Powdery pernasal compositions.
ZA991014B (en) Pesticidal compositions.
HK1039119A1 (en) Dihydropyrimidines.
ZA99254B (en) Benzosulfone derivatives.
HK1038884A1 (en) Medicinal compositions.
IL143939A0 (en) Combination chemotherapy
ZA991272B (en) Novel thiobenzamides.
HK1042999A1 (en) Wdm-channel equalizer.
ZA200005510B (en) Pharmaceutical composition.
HK1041482A1 (en) Naphtho-and dihydrobenzo-thiophene derivatives as cytotoxic antitumor agents.
ZA992443B (en) Hydroxy-methyl-hexanones.
ZA991550B (en) Cyclohexanediole derivatives.
ZA995325B (en) Methylcyclotetradec-5-en-1-ones.
ZA993123B (en) Trisresorcinyltriazines.
HK1036280A1 (en) Antivirals.
ZA993197B (en) Pesticidal composition.
ZA995239B (en) Pesticidal compositions.
HK1044117A1 (en) Pharmaceutical composition.
ZA200006118B (en) Novel composition.
ZA99890B (en) Pharmaceutical compositions.
ZA200000192B (en) Novel composition.